Some things old, new and borrowed: Delivery of dabrafenib and vemurafenib to melanoma cells via self-assembled nanomicelles based on an amphiphilic dendrimer

Two clinically approved anticancer drugs targeting BRAF in melanoma patients - dabrafenib (DAB) and vemurafenib (VEM) - have been successfully encapsulated into nanomicelles formed upon self-assembly of an amphiphilic dendrimer AD based on two C18 aliphatic chains and a G2 PAMAM head. The process resulted in the formation of well-defined (similar to 10 nm) core-shell nanomicelles (NMs) with excellent encapsulation efficiency (similar to 70% for DAB and similar to 60% for VEM) and good drug loading capacity (similar to 27% and similar to 24% for DAB and VEM, respectively). Dynamic light scattering (DLS), transmission electron microscopy (TEM), small-angle x-ray scattering (SAXS), nuclear magnetic resonance (NMR), isothermal titration calorimetry (ITC), and molecular simulation (MS) experiments were used, respectively, to determine the size and structure of the empty and drug-loaded nanomicelles (DLNMs), along with the interactions between the NMs and their cargoes. The in vitro release data revealed profiles governed by Fickian diffusion; moreover, for both anticancer molecules, an acidic environment (pH = 5.0) facilitated drug release with respect to physiological pH conditions (pH = 7.4). Finally, both DAB- and VEM-loaded NMs elicited enhanced response with respect to free drug treatments in 4 different melanoma cell lines.

Automated summary

Dabrafenib (DAB) and vemurafenib (VEM), two clinically approved anticancer drugs, were successfully encapsulated into nanomicelles formed by an amphiphilic dendrimer. The nanomicelles demonstrated well-defined structure, high encapsulation efficiency, good drug loading capacity, and pH-dependent drug release. In vitro experiments showed that the drug-loaded nanomicelles exhibited enhanced response compared to free drugs in melanoma cell lines.